The National Medical Products Administration (NMPA) recently approved  Desmodium Styracifolium Flavonoids Capsule (Chinese name by Pinyin: Guangjinqiancao Zonghuangtong Jiaonang) for marketing, an innovative traditional Chinese medicine (TCM). The main ingredient of the drug is the flavonoids composition extracted from Desmodium Styracifolium. The Marketing Authorization Holder of this medical product is Wuhan Guanggu Humanwell Biomedical Co Ltd.

Randomized, double-blinded and placebo-controlled multicenter clinical trials were conducted to evaluate the safety and efficacy of the drug. The results showed statistical differences between the placebo-controlled group and treatment group, which indicates that the drug can be used for the treatment of ureteral calculi with syndrome of accumulated damp-heat.

The marketing of the drug will provide a new treatment option for the patients. The NMPA will strengthen post-marketing surveillance to ensure the safety of public medication.